FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

Comparison of Relapse Rates in Multiple Sclerosis Patients Switching from Glatiramer Acetate (Copaxone) to Fingolimod (Gilenya) versus Those Remaining on Glatiramer Acetate: STUDY































Abstract

Objective:
To compare relapse rates in multiple sclerosis (MS) patients switching from glatiramer acetate (GA) to fingolimod (FTY) versus those continuing treatment with GA.

Background:
Given the growing number of DMTs available for treatment of relapsing-remitting MS (RRMS), evidence generation to inform the use of individual agents and their treatment patterns is increasingly important.

Design/Methods:
A retrospective study was conducted using MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases. MS patients (蠅1 claim ICD-9=340) treated with GA in the 12 months prior to their first prescription of the DMT of interest (pre-period) during 1/1/2010-9/30/2012 were identified and assigned to the treatment group is they switched to FTY or the control group if they remained on GA (GA→FTY versus GA only, respectively). Both groups were followed for twelve months (post-period). Demographics, clinical characteristics, and medication use were assessed in the pre-period. Analyses of trends and difference-in-differences (DD) were applied to evaluate relapse rates by group. Odds ratio of relapse between groups was estimated using logistic regression.

Results:
6,779 patients were included (GA only=6,416; GA→FTY=363). Significant differences were observed between groups in age, geographic region, non-DMT medication utilization, MS-related symptoms, and proportion of days covered. A decline in the percentage of relapses occurred in both groups in the post- versus pre-periods (GA→FTY=16.2[percnt]; GA only=2.5[percnt]). DD analyses indicated a 13.7[percnt] relapse rate reduction associated with GA→FTY versus GA only. Comparing the pre-period and the post-period, the odds of relapse was 2.63 and 1.22 respectively for GA→FTY versus GA only.

Conclusions:
Compared with patients remaining on GA, patients switching from GA to FTY demonstrated significant reductions in relapses over the 1-year timeframe. Characterization of key factors when considering a switch from GA to FTY is essential to informing appropriate treatment. Study Supported by: Novartis, KMK Consulting

Story Source: The above story is based on materials provided by NEUROLOGY
Note: Materials may be edited for content and length

Labels: , ,



Go to Newer News Go to Older News